datetime,channel,message_id,url,raw,lm_json
2025-12-08T16:31:24+00:00,@bezrec,6909,https://t.me/bezrec/6909,"""–ë–µ–∑ —Ä–µ—Ü–µ–ø—Ç–∞"" —Ç–µ–ø–µ—Ä—å –≤ MAX –î—Ä—É–∑—å—è, —É –Ω–∞—à–µ–≥–æ –∫–∞–Ω–∞–ª–∞ –ø–æ—è–≤–∏–ª—Å—è –æ—Ñ–∏—Ü–∏–∞–ª—å–Ω—ã–π –∞–∫–∫–∞—É–Ω—Ç –≤ –æ—Ç–µ—á–µ—Å—Ç–≤–µ–Ω–Ω–æ–º –º–µ—Å—Å–µ–Ω–¥–∂–µ—Ä–µ MAX. –¢—É–¥–∞ –±—É–¥—É—Ç –∞–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∏ —Ç—Ä–∞–Ω—Å–ª–∏—Ä–æ–≤–∞—Ç—å—Å—è –≤—Å–µ –Ω–∞—à–∏ –ø—É–±–ª–∏–∫–∞—Ü–∏–∏ —Å —É—á—ë—Ç–æ–º —Ñ—É–Ω–∫—Ü–∏–æ–Ω–∞–ª—å–Ω—ã—Ö –≤–æ–∑–º–æ–∂–Ω–æ—Å—Ç–µ–π –ø–ª–∞—Ç—Ñ–æ—Ä–º—ã. –≠—Ç–æ—Ç —à–∞–≥ –≤–æ –º–Ω–æ–≥–æ–º –≤—ã–Ω—É–∂–¥–µ–Ω–Ω—ã–π. –ú—ã —Ö–æ—Ç–∏–º —Å–æ—Ö—Ä–∞–Ω–∏—Ç—å —Å–≤—è–∑—å —Å –∞—É–¥–∏—Ç–æ—Ä–∏–µ–π –≤ –ª—é–±—ã—Ö –Ω–µ–ø—Ä–µ–¥–≤–∏–¥–µ–Ω–Ω—ã—Ö –æ–±—Å—Ç–æ—è—Ç–µ–ª—å—Å—Ç–≤–∞—Ö, –∫–æ—Ç–æ—Ä—ã–µ –º–æ–≥—É—Ç –∑–∞—Ç—Ä–æ–Ω—É—Ç—å —Ä–∞–±–æ—Ç—É Telegram. ‚û°Ô∏è–ü–æ–¥–ø–∏—Å—ã–≤–∞–π—Ç–µ—Å—å –Ω–∞ –Ω–∞—Å –≤ MAX, —á—Ç–æ–±—ã –≤—Å–µ–≥–¥–∞ –æ—Å—Ç–∞–≤–∞—Ç—å—Å—è –Ω–∞ —Å–≤—è–∑–∏!","{""skip"": true}"
2025-12-08T14:31:11+00:00,@bezrec,6908,https://t.me/bezrec/6908,"Xzibit –∑–∞–º–µ—á–µ–Ω –≤ –ú–æ—Å–∫–≤–µ –≤ ¬´–∫–æ–º–ø–∞–Ω–∏–∏¬ª –¢–∏—Ä–∑–µ—Ç—Ç—ã. –ê–º–µ—Ä–∏–∫–∞–Ω—Å–∫–∏–π —Ä—ç–ø–µ—Ä –æ—Ç–¥—ã—Ö–∞–ª –ø–æ—Å–ª–µ –∫–æ–Ω—Ü–µ—Ä—Ç–∞ –≤ –º–æ—Å–∫–æ–≤—Å–∫–æ–º –æ—Ç–µ–ª–µ Carlton. –ù–∞ –≤–∏–¥–µ–æ –∞—Ä—Ç–∏—Å—Ç –≥–æ—Ç–æ–≤–∏—Ç—Å—è —Å—ä–µ—Å—Ç—å –≤–Ω—É—à–∏—Ç–µ–ª—å–Ω–æ–≥–æ —Ä–∞–∑–º–µ—Ä–∞ –±—É—Ä–≥–µ—Ä –∏ –æ–¥–Ω–æ–≤—Ä–µ–º–µ–Ω–Ω–æ —Å –∏–Ω—Ç–µ—Ä–µ—Å–æ–º —Ä–∞–∑–≥–ª—è–¥—ã–≤–∞–µ—Ç –ø—Ä–µ–ø–∞—Ä–∞—Ç –¥–ª—è –ø–æ—Ö—É–¥–µ–Ω–∏—è –æ—Ç ¬´–ü—Ä–æ–º–æ–º–µ–¥–∞¬ª. –ñ–¥—ë–º –Ω–æ–≤—ã–π —Ö–∏—Ç –ø—Ä–æ –¢–∏—Ä–∑–µ—Ç—Ç—É, –Ω–æ —É–∂–µ –Ω–∞ –∞–Ω–≥–ª–∏–π—Å–∫–æ–º? –§–ê–° –ø—Ä–æ—Ç–∏–≤ —Ç–∞–∫–æ–≥–æ –Ω–µ –≤–æ–∑—Ä–∞–∂–∞–µ—Ç. ‚Ñ¢ –ë–µ–∑ —Ä–µ—Ü–µ–ø—Ç–∞","{""skip"": true}"
2025-12-08T11:45:24+00:00,@bezrec,6907,https://t.me/bezrec/6907,"¬´–ë–∏–Ω–Ω–æ—Ñ–∞—Ä–º¬ª —Å –ø–æ–º–æ—â—å—é –∫–∏—Ç–∞–π—Ü–µ–≤ ¬´–ø–æ–¥–≤–∏–Ω–µ—Ç¬ª Sanofi —Å –¥—É–ø–∏–ª—É–º–∞–±–æ–º. ¬´–ë–∏–Ω–Ω–æ—Ñ–∞—Ä–º –ì—Ä—É–ø–ø¬ª –¥–æ–≥–æ–≤–æ—Ä–∏–ª–∞—Å—å —Å –∫–∏—Ç–∞–π—Å–∫–æ–π Mabwell –æ –ª–æ–∫–∞–ª–∏–∑–∞—Ü–∏–∏ –≤ –†–æ—Å—Å–∏–∏ –¥—É–ø–∏–ª—É–º–∞–±–∞ –ø—Ä–æ—Ç–∏–≤ –∞—Ç–æ–ø–∏—á–µ—Å–∫–æ–≥–æ –¥–µ—Ä–º–∞—Ç–∏—Ç–∞ –∏ –±—Ä–æ–Ω—Ö–∏–∞–ª—å–Ω–æ–π –∞—Å—Ç–º—ã –Ω–∞ –æ—Å–Ω–æ–≤–µ –º–æ–Ω–æ–∫–ª–æ–Ω–∞–ª—å–Ω—ã—Ö –∞–Ω—Ç–∏—Ç–µ–ª. –ü–æ –¥–∞–Ω–Ω—ã–º –ì–†–õ–°, –µ–¥–∏–Ω—Å—Ç–≤–µ–Ω–Ω–æ–µ –∑–∞—Ä–µ–≥–∏—Å—Ç—Ä–∏—Ä–æ–≤–∞–Ω–Ω–æ–µ –≤ –†–§ —Å—Ä–µ–¥—Å—Ç–≤–æ —Å —ç—Ç–∏–º –ú–ù–ù ‚Äî –î—É–ø–∏–∫—Å–µ–Ω—Ç –æ—Ç —Ñ—Ä–∞–Ω—Ü—É–∑—Å–∫–æ–π Sanofi. –ö–∞–∫ –ø–æ–¥—Å—á–∏—Ç–∞–ª–∏ –¥–ª—è ¬´–™¬ª –≤ DSM Group, –∑–∞ 10 –º–µ—Å—è—Ü–µ–≤ 2025 –≥–æ–¥–∞ –≤ —è–Ω–≤–∞—Ä–µ‚Äî–æ–∫—Ç—è–±—Ä–µ –≤ –†–æ—Å—Å–∏–∏ –±—ã–ª–æ —Ä–µ–∞–ª–∏–∑–æ–≤–∞–Ω–æ 45 —Ç—ã—Å. –ø–∞—á–µ–∫ –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤ —Å –¥—É–ø–∏–ª—É–º–∞–±–æ–º –Ω–∞ —Å—É–º–º—É 3,5 –º–ª—Ä–¥ —Ä—É–±–ª–µ–π. –≠—Ç–æ –Ω–∞ 29% –±–æ–ª—å—à–µ –≥–æ–¥ –∫ –≥–æ–¥—É –≤ –Ω–∞—Ç—É—Ä–∞–ª—å–Ω–æ–º –∏ 30% –≤ –¥–µ–Ω–µ–∂–Ω–æ–º –≤—ã—Ä–∞–∂–µ–Ω–∏–∏ –≥–æ–¥ –∫ –≥–æ–¥—É. –ü—Ä–µ–ø–∞—Ä–∞—Ç —Å—Ç–æ–∏–º–æ—Å—Ç—å—é 76,7 —Ç—ã—Å. —Ä—É–±–ª–µ–π –∑–∞ —É–ø–∞–∫–æ–≤–∫—É —Ä–∞—Å—Ö–æ–¥–∏—Ç—Å—è –≤ –æ—Å–Ω–æ–≤–Ω–æ–º —á–µ—Ä–µ–∑ –≥–æ—Å–∑–∞–∫—É–ø–∫–∏. –£ –∫–æ–º–ø–∞–Ω–∏–∏ –†—É—Å—Ç–µ–º–∞ –ú—É—Ä–∞—Ç–æ–≤–∞ —É–∂–µ –µ—Å—Ç—å –æ–ø—ã—Ç —Å–æ—Ç—Ä—É–¥–Ω–∏—á–µ—Å—Ç–≤–∞ —Å Mabwell –≤ –æ–±–ª–∞—Å—Ç–∏ –ª–æ–∫–∞–ª–∏–∑–∞—Ü–∏–∏ –º–æ–Ω–æ–∫–ª–æ–Ω–∞–ª—å–Ω—ã—Ö –∞–Ω—Ç–∏—Ç–µ–ª. –í –Ω–∞—á–∞–ª–µ 2026 –≥–æ–¥–∞ –ø–∞—Ä—Ç–Ω—ë—Ä—ã –ø–ª–∞–Ω–∏—Ä—É—é—Ç –≤—ã–≤–µ—Å—Ç–∏ –Ω–∞ —Ä—ã–Ω–æ–∫ –±–∏–æ—Å–∏–º–∏–ª—è—Ä—ã –∞–¥–∞–ª–∏–º—É–º–∞–±–∞ –ø—Ä–æ—Ç–∏–≤ —Ä–µ–≤–º–∞—Ç–æ–∏–¥–Ω–æ–≥–æ –∞—Ä—Ç—Ä–∏—Ç–∞ –∏ –¥–µ–Ω–æ—Å—É–º–∞–±–∞ –æ—Ç –æ—Å—Ç–µ–æ–ø–æ—Ä–æ–∑–∞, –ø—Ä–æ–∏–∑–≤–µ–¥–µ–Ω–Ω—ã–µ –Ω–∞ –ø–ª–æ—â–∞–¥–∫–µ –≤ –ó–µ–ª–µ–Ω–æ–≥—Ä–∞–¥–µ. –ü–æ —Å–ª–æ–≤–∞–º –¥–∏—Ä–µ–∫—Ç–æ—Ä–∞ –ø–æ —Ä–∞–∑–≤–∏—Ç–∏—é RNC Pharma –ù–∏–∫–æ–ª–∞—è –ë–µ—Å–ø–∞–ª–æ–≤–∞, –ø—Ä–∏–æ–±—Ä–µ—Ç–µ–Ω–∏–µ –ø—Ä–∞–≤ –Ω–∞ –∫–∏—Ç–∞–π—Å–∫–∏–µ –ø—Ä–µ–ø–∞—Ä–∞—Ç—ã –¥–ª—è –¥–∞–ª—å–Ω–µ–π—à–µ–π –∫–æ–º–º–µ—Ä—Ü–∏–∞–ª–∏–∑–∞—Ü–∏–∏ ‚Äî –Ω–æ—Ä–º–∞–ª—å–Ω–∞—è –º–∏—Ä–æ–≤–∞—è –ø—Ä–∞–∫—Ç–∏–∫–∞. –í –†–æ—Å—Å–∏–∏ –æ–Ω–∞ —Ç–æ–∂–µ –Ω–∞–±–∏—Ä–∞–µ—Ç –æ–±–æ—Ä–æ—Ç—ã. –¢–∞–∫, –≤ –Ω–æ—è–±—Ä–µ 2024 –≥–æ–¥–∞ ¬´–ü–µ—Ç—Ä–æ–≤–∞–∫—Å¬ª –∑–∞—Ä–µ–≥–∏—Å—Ç—Ä–∏—Ä–æ–≤–∞–ª–∞ —Å–æ–≤–º–µ—Å—Ç–Ω–æ —Å Jiangsu Hengrui –∫–∞–º—Ä–µ–ª–∏–∑—É–º–∞–± –¥–ª—è —Ç–µ—Ä–∞–ø–∏–∏ —Ä–∞–∫–∞ –Ω–æ—Å–æ–≥–ª–æ—Ç–∫–∏ –∏ –ø–∏—â–µ–≤–æ–¥–∞. –ó–∞ —Å—É–¥—å–±—É —Ñ—Ä–∞–Ω—Ü—É–∑—Å–∫–æ–≥–æ –¥—É–ø–∏–ª—É–º–∞–±–∞ –ø–µ—Ä–µ–∂–∏–≤–∞–µ—Ç ¬´–ò–Ω—Ñ–∞—Ä–º–∞¬ª: –ï—Å–ª–∏ –≤ –°–ó–õ–° –ø–æ–ø–∞–¥—É—Ç –ª–µ–∫–∞—Ä—Å—Ç–≤–∞ –ø–æ–¥ –ø–∞—Ç–µ–Ω—Ç–∞–º–∏, –Ω–µ–¥–æ–±—Ä–æ—Å–æ–≤–µ—Å—Ç–Ω—ã–µ –ø—Ä–æ–∏–∑–≤–æ–¥–∏—Ç–µ–ª–∏ –ø–æ–ª—É—á–∞—Ç –∫–∞—Ä—Ç-–±–ª–∞–Ω—à –Ω–∞ –∑–∞–≤–æ–µ–≤–∞–Ω–∏–µ —Ä—ã–Ω–∫–∞, –∞ –∏–Ω–æ—Å—Ç—Ä–∞–Ω–Ω—ã–µ –∫–æ–º–ø–∞–Ω–∏–∏ –ø–æ—Ç–µ—Ä—è—é—Ç —Å—Ç–∏–º—É–ª –≤—ã–≤–æ–¥–∏—Ç—å –ø—Ä–µ–ø–∞—Ä–∞—Ç—ã ¬´–ø—Ä–æ—Ä—ã–≤–Ω—ã—Ö —Ç–µ—Ä–∞–ø–∏–π¬ª. –í —á–∞—Å—Ç–Ω–æ—Å—Ç–∏, –ø–æ–¥ —É–¥–∞—Ä –º–æ–≥—É—Ç –ø–æ–ø–∞—Å—Ç—å –∏–Ω—Å—É–ª–∏–Ω –≥–ª–∞—Ä–≥–∏–Ω, –∫–æ–º–±–∏–Ω–∞—Ü–∏—è –∏–Ω—Å—É–ª–∏–Ω–∞ –≥–ª–∞—Ä–≥–∏–Ω–∞ —Å –ª–∏–∫—Å–∏—Å–µ–Ω–∞—Ç–∏–¥–æ–º –∏ –∞–ª–∏—Ä–æ–∫—É–º–∞–±, –¥—É–ø–∏–ª—É–º–∞–±, –∑–∞—â–∏—â–µ–Ω–Ω—ã–µ –ø–∞—Ç–µ–Ω—Ç–æ–º –≤ —Ç–µ—á–µ–Ω–∏–µ –ø—è—Ç–∏ –ª–µ—Ç –∏ –±–æ–ª–µ–µ, ‚Äî –≥–æ–≤–æ—Ä–∏–ª–æ—Å—å –≤ –æ–±—Ä–∞—â–µ–Ω–∏–∏, –Ω–∞–ø—Ä–∞–≤–ª–µ–Ω–Ω–æ–º –æ—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏–µ–π –≤ –ú–∏–Ω–ø—Ä–æ–º—Ç–æ—Ä–≥. ‚Ñ¢ –ë–µ–∑ —Ä–µ—Ü–µ–ø—Ç–∞","{
  ""skip"": false,
  ""country"": ""global"",
  ""topic"": ""tenders, import_export, shortage, demand"",
  ""impact"": ""high"",
  ""english"": ""The acquisition of rights to French Dupilumab for further commercialization is a normal global practice. However, 'Infarma' expresses concern that if the medicines under patents are approved in SZZLS, it could lead to a lack of incentive for foreign companies to develop breakthrough therapies. The company 'Petrovax' has registered Camrelizumab for the treatment of nasopharyngeal and esophageal cancer in November 2024. 'Infarma' is worried that if the patents for drugs like insulin glargine, combination of insulin glargine with lisixenatide and alirokumab are approved, which are protected for five years or more, it could result in a shortage of these drugs and hinder the development of breakthrough therapies.""
}"
2025-12-08T08:50:01+00:00,@bezrec,6906,https://t.me/bezrec/6906,"–ö–æ-–î–∞–ª—å–Ω–µ–≤–∞ –≤—Å—Ç–∞–Ω–µ—Ç ¬´–ö–†–ö–ê¬ª –≤ –º–∏–ª–ª–∏–æ–Ω. –í –º–∞–µ 2025 –≥–æ–¥–∞ –§–ê–° –æ—à—Ç—Ä–∞—Ñ–æ–≤–∞–ª–∞ —Å–ª–æ–≤–µ–Ω—Å–∫—É—é —Ñ–∞—Ä–º–∫–æ–º–ø–∞–Ω–∏—é –∑–∞ –Ω–∞—Ä—É—à–µ–Ω–∏–µ –∞–Ω—Ç–∏–º–æ–Ω–æ–ø–æ–ª—å–Ω–æ–≥–æ –∑–∞–∫–æ–Ω–æ–¥–∞—Ç–µ–ª—å—Å—Ç–≤–∞ –∏ –Ω–µ–æ–±–æ—Å–Ω–æ–≤–∞–Ω–Ω–æ–µ –ø–æ–≤—ã—à–µ–Ω–∏–µ –æ—Ç–ø—É—Å–∫–Ω—ã—Ö —Ü–µ–Ω –Ω–∞ 2 –∏–∑ 6 –¥–æ–∑–∏—Ä–æ–≤–æ–∫ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞ –ö–æ-–î–∞–ª—å–Ω–µ–≤–∞ –Ω–∞ 10-16%. –†–µ–≥—É–ª—è—Ç–æ—Ä –∑–∞–∏–Ω—Ç–µ—Ä–µ—Å–æ–≤–∞–ª—Å—è ¬´–ö–†–ö–ê¬ª –∏–∑-–∑–∞ –ª–µ–∫–∞—Ä—Å—Ç–≤–∞ –æ—Ç –¥–∞–≤–ª–µ–Ω–∏—è —Å –ú–ù–ù –∞–º–ª–æ–¥–∏–ø–∏–Ω + –∏–Ω–¥–∞–ø–∞–º–∏–¥ + –ø–µ—Ä–∏–Ω–¥–æ–ø—Ä–∏–ª –ø–æ—Å–ª–µ –∂–∞–ª–æ–± –ø–æ–∫—É–ø–∞—Ç–µ–ª–µ–π. ¬´–ö–†–ö–ê¬ª –¥–æ–ª–∂–Ω–∞ –±—ã–ª–∞ —É—Å—Ç—Ä–∞–Ω–∏—Ç—å –Ω–∞—Ä—É—à–µ–Ω–∏—è –≤ —Ç–µ—á–µ–Ω–∏–µ –º–µ—Å—è—Ü–∞, –Ω–æ —Ç–∞–∫ –∏ –Ω–µ —É—Å—Ç–∞–Ω–æ–≤–∏–ª–∞ —ç–∫–æ–Ω–æ–º–∏—á–µ—Å–∫–∏ –æ–±–æ—Å–Ω–æ–≤–∞–Ω–Ω—ã–µ —Ü–µ–Ω—ã –Ω–∞ –Ω–µ –∏–º–µ—é—â–∏–π –∞–Ω–∞–ª–æ–≥–æ–≤ –ø—Ä–µ–ø–∞—Ä–∞—Ç –æ—Ç –≥–∏–ø–µ—Ä—Ç–æ–Ω–∏–∏. –û–±—â–∞—è —Å—É–º–º–∞ –Ω–∞–ª–æ–∂–µ–Ω–Ω—ã—Ö –Ω–∞ –æ—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏—é —à—Ç—Ä–∞—Ñ–æ–≤ –Ω–∞ –¥–∞–Ω–Ω—ã–π –º–æ–º–µ–Ω—Ç —Å–æ—Å—Ç–∞–≤–ª—è–µ—Ç 1 050 000 —Ä—É–±–ª–µ–π, —Å–æ–æ–±—â–∏–ª–∏ –∞–Ω—Ç–∏–º–æ–Ω–æ–ø–æ–ª—å—â–∏–∫–∏. ‚Ñ¢ –ë–µ–∑ —Ä–µ—Ü–µ–ø—Ç–∞","{
  ""skip"": false,
  ""country"": ""global"",
  ""topic"": ""sanctions, shortage"",
  ""impact"": ""high"",
  ""english"": ""The FAS fined the Slovenian pharmaceutical company 'KRCA' for antitrust violations and unjustified price increases on two out of six dosage forms of the hypertension drug Co-Dalene by 10-16%. The regulator is interested in 'KRCA' due to the hypertension drug with the MN number amlopidine + indapamide + perindopril without an analog. 'KRCA' was required to rectify the violations within a month, but did not set economically justified prices for the drug. The total amount of sanctions imposed on the organization is currently 1,050,000 rubles, according to antitrust officials.""
}"
2025-12-08T05:50:02+00:00,@bezrec,6905,https://t.me/bezrec/6905,"¬´–ê–∫—Å–µ–ª—å—Ñ–∞—Ä–º—É¬ª —Ä–∞–∑—Ä–µ—à–∏–ª–∏ —Ç–æ—Ä–≥–æ–≤–∞—Ç—å –∞–Ω–∞–ª–æ–≥–æ–º –î–∂–∞–∫–∞–≤–∏. –ê—Ä–±–∏—Ç—Ä–∞–∂–Ω—ã–π —Å—É–¥ –ú–æ—Å–∫–≤—ã –æ—Ç–º–µ–Ω–∏–ª —Ä–µ—à–µ–Ω–∏–µ –§–ê–°, –∑–∞–ø—Ä–µ—â–∞—é—â–µ–µ —Ä–æ—Å—Å–∏–π—Å–∫–æ–π –∫–æ–º–ø–∞–Ω–∏–∏ –≤—ã–≤–æ–¥–∏—Ç—å –Ω–∞ —Ä—ã–Ω–æ–∫ —Å–≤–æ–π —Ä—É–∫—Å–æ–ª–∏—Ç–∏–Ω–∏–± –∏–∑-–∑–∞ –Ω–∞—Ä—É—à–µ–Ω–∏—è –∑–∞–∫–æ–Ω–∞ –æ –∑–∞—â–∏—Ç–µ –∫–æ–Ω–∫—É—Ä–µ–Ω—Ü–∏–∏. –í–æ–∑–≤—Ä–∞—â–∞—Ç—å –≤ –±—é–¥–∂–µ—Ç 960,8 –º–ª–Ω —Ä—É–±–ª–µ–π, –ø–æ–ª—É—á–µ–Ω–Ω—ã–µ –æ—Ç –ø—Ä–æ–¥–∞–∂–∏ –¥–∂–µ–Ω–µ—Ä–∏–∫–∞, —Ç–æ–∂–µ –Ω–µ –ø—Ä–∏–¥—ë—Ç—Å—è. –ù–∞–ø–æ–º–Ω–∏–º, —Å –∑–∞—è–≤–ª–µ–Ω–∏–µ–º –æ –Ω–µ–¥–æ–±—Ä–æ—Å–æ–≤–µ—Å—Ç–Ω—ã—Ö –¥–µ–π—Å—Ç–≤–∏—è—Ö —Å–æ —Å—Ç–æ—Ä–æ–Ω—ã –∫–æ–Ω–∫—É—Ä–µ–Ω—Ç–æ–≤ –≤ –§–ê–° –æ–±—Ä–∞—Ç–∏–ª–∏—Å—å –ø–æ—Å—Ç–∞–≤—â–∏–∫–∏ –æ—Ä–∏–≥–∏–Ω–∞–ª—å–Ω—ã—Ö –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤, —Ä–∞–±–æ—Ç–∞—é—â–∏–µ –≤ –†–æ—Å—Å–∏–∏. –ó–∞ —ç—Ç–æ –≤—Ä–µ–º—è ¬´–ê–∫—Å–µ–ª—å–§–∞—Ä–º¬ª —É—Å–ø–µ–ª –ø–æ–ª—É—á–∏—Ç—å —Ä–∞–∑—Ä–µ—à–µ–Ω–∏–µ –Ω–∞ —Ä–µ–∞–ª–∏–∑–∞—Ü–∏—é 9,7 —Ç—ã—Å. —É–ø–∞–∫–æ–≤–æ–∫ –ø—Ä–æ—Ç–∏–≤–æ–æ–ø—É—Ö–æ–ª–µ–≤–æ–≥–æ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞. –û—Ä–∏–≥–∏–Ω–∞–ª—å–Ω—ã–π –î–∂–∞–∫–∞–≤–∏ –∑–∞—â–∏—â–µ–Ω –ø–∞—Ç–µ–Ω—Ç–æ–º –¥–æ –∫–æ–Ω—Ü–∞ 2028 –≥–æ–¥–∞. –í ¬´–ê–∫—Å–µ–ª—å—Ñ–∞—Ä–º–µ¬ª –¥–æ–≤–æ–ª—å–Ω—ã —Ä–µ—à–µ–Ω–∏–µ–º —Å—É–¥–∞, –∫–æ—Ç–æ—Ä–æ–µ, –∫–∞–∫ —Ä–∞—Å—Å–∫–∞–∑–∞–ª–∏ –≤ –∫–æ–º–ø–∞–Ω–∏–∏ ¬´–™¬ª, ¬´—É–∫—Ä–µ–ø–ª—è–µ—Ç –≥–∞—Ä–∞–Ω—Ç–∏–∏ –µ–≥–æ –¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç–∏ –≤ —Ä–∞–º–∫–∞—Ö –≥–æ—Å—É–¥–∞—Ä—Å—Ç–≤–µ–Ω–Ω—ã—Ö –ø—Ä–æ–≥—Ä–∞–º–º –ª—å–≥–æ—Ç–Ω–æ–≥–æ –æ–±–µ—Å–ø–µ—á–µ–Ω–∏—è¬ª. –§–ê–° –∏ Novartis –ø–ª–∞–Ω–∏—Ä—É—é—Ç –µ–≥–æ –æ–±–∂–∞–ª–æ–≤–∞—Ç—å. –î–µ–π—Å—Ç–≤—É—é—â–∞—è –ø–∞—Ç–µ–Ω—Ç–Ω–∞—è –∑–∞—â–∏—Ç–∞ –∫—Ä–∞–π–Ω–µ –≤–∞–∂–Ω–∞ –¥–ª—è –ø–æ–≤—ã—à–µ–Ω–∏—è –ø—Ä–µ–¥—Å–∫–∞–∑—É–µ–º–æ—Å—Ç–∏ –∏ –ø—Ä–∞–≤–æ–≤–æ–π –æ–ø—Ä–µ–¥–µ–ª–µ–Ω–Ω–æ—Å—Ç–∏ –¥–ª—è –≤—Å–µ—Ö –∑–∞–∏–Ω—Ç–µ—Ä–µ—Å–æ–≤–∞–Ω–Ω—ã—Ö —Å—Ç–æ—Ä–æ–Ω, –∫–æ—Ç–æ—Ä—ã–µ –≤–Ω–æ—Å—è—Ç –≤–∫–ª–∞–¥ –≤ —Å–∏—Å—Ç–µ–º—É –æ–±—â–µ—Å—Ç–≤–µ–Ω–Ω–æ–≥–æ –∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è, ‚Äî –∑–∞—è–≤–∏–ª–∏ —à–≤–µ–π—Ü–∞—Ä—Ü—ã. ¬´–ê–∫—Å–µ–ª—å—Ñ–∞—Ä–º—É¬ª –ø–æ—Å–ª–µ–¥–Ω–µ–µ –≤—Ä–µ–º—è –≤–µ–∑—ë—Ç –Ω–∞ —Å—É–¥–µ–±–Ω—ã–µ —Ä–µ—à–µ–Ω–∏—è. –†–∞–Ω–µ–µ –∫–æ–º–ø–∞–Ω–∏–∏ —É–¥–∞–ª–æ—Å—å –æ—Å–ø–æ—Ä–∏—Ç—å –∞–Ω–∞–ª–æ–≥–∏—á–Ω—ã–µ –ø—Ä–µ–¥–ø–∏—Å–∞–Ω–∏—è –∞–Ω—Ç–∏–º–æ–Ω–æ–ø–æ–ª—å—â–∏–∫–æ–≤ –ø–æ –¥–∂–µ–Ω–µ—Ä–∏–∫—É –ò–Ω–ª–∏—Ç—ã (–∞–∫—Å–∏—Ç–∏–Ω–∏–±) –æ—Ç Pfizer –∏ –∞–Ω–∞–ª–æ–≥—É –¢–∞–≥—Ä–∏—Å—Å–æ (–æ—Å–∏–º–µ—Ä—Ç–∏–Ω–∏–±–∞) –æ—Ç AstraZeneca. –ù–∞ —Å—Ç–æ—Ä–æ–Ω—É –§–ê–° —Å—É–¥ –≤—Å—Ç–∞–ª —Ç–æ–ª—å–∫–æ –≤ —Å–ª—É—á–∞–µ —Å –±–æ–∑—É—Ç–∏–Ω–∏–±–æ–º. –ü–æ –¥–∞–Ω–Ω—ã–º –ø–ª–∞—Ç—Ñ–æ—Ä–º—ã –ø–æ —Ä–∞–±–æ—Ç–µ —Å —Ç–µ–Ω–¥–µ—Ä–∞–º–∏ ¬´–¢–µ–Ω–¥–µ—Ä–ø–ª–∞–Ω¬ª, —Å —è–Ω–≤–∞—Ä—è –ø–æ –∏—é–Ω—å 2025 –≥–æ–¥–∞ –≥–æ—Å–∑–∞–∫—É–ø–∫–∏ —ç—Ç–∏—Ö —á–µ—Ç—ã—Ä—ë—Ö –¥–∂–µ–Ω–µ—Ä–∏–∫–æ–≤ –≤—ã—Ä–æ—Å–ª–∏ –Ω–∞ 35% –∏ –¥–æ—Å—Ç–∏–≥–ª–∏ 11,3 –º–ª—Ä–¥ —Ä—É–±–ª–µ–π. ‚Ñ¢ –ë–µ–∑ —Ä–µ—Ü–µ–ø—Ç–∞","{
  ""skip"": false,
  ""country"": ""global"",
  ""topic"": ""import_export, sanctions, shortage, regulation, registration, reimbursement"",
  ""impact"": ""high"",
  ""english"": ""The Arbitration Court of Moscow overturned a FAS decision prohibiting the Russian company 'Akselfarm' from entering the market with its rivoli. The court ruled that the company can now sell generic versions of Jakaivi, which is protected by a patent until 2028. The company 'Akselfarm' expressed satisfaction with the ruling, stating that it strengthens the availability of the drug within government programs. Novartis and FAS plan to appeal this decision. The companies 'Akselfarm' have had success in court rulings, including against generics of Inlyta (axitinib) from Pfizer and Tagrisso (osimertinib) from AstraZeneca. Government procurement of these four generics has increased by 35% to 11.3 billion rubles from January to June 2025.""
}"
2025-12-08T16:36:05+00:00,@medpharm,13926,https://t.me/medpharm/13926,"–ü—Ä–æ—Ç–µ—Å—Ç–∏—Ä–æ–≤–∞–Ω–∞ –ø–µ—Ä–≤–∞—è –ò–ò-–ø–ª–∞—Ç—Ñ–æ—Ä–º–∞ –¥–ª—è –ø–æ–¥–¥–µ—Ä–∂–∫–∏ –ø—Å–∏—Ö–æ–ª–æ–≥–æ–≤, –ø–æ–≤—ã—à–∞—é—â–∞—è –¥–æ—Å—Ç—É–ø–Ω–æ—Å—Ç—å –∏ –∫–∞—á–µ—Å—Ç–≤–æ –ø–æ–º–æ—â–∏ –ø–∞—Ü–∏–µ–Ω—Ç–∞–º. –¢–µ—Å—Ç–∏—Ä–æ–≤–∞–Ω–∏–µ –ø–æ–∫–∞–∑–∞–ª–æ –¥–æ 95% –ø–æ–ª–µ–∑–Ω—ã—Ö —Ä–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–π –∏ —ç–∫–æ–Ω–æ–º–∏—é 20‚Äî30% —Ä–∞–±–æ—á–µ–≥–æ –≤—Ä–µ–º–µ–Ω–∏ –±–ª–∞–≥–æ–¥–∞—Ä—è –∞–≤—Ç–æ–º–∞—Ç–∏–∑–∞—Ü–∏–∏ —Ä—É—Ç–∏–Ω–Ω—ã—Ö –∑–∞–¥–∞—á. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjbWT #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–¢–µ—Ö–Ω–æ–ª–æ–≥–∏–∏ #–û—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏—è_–∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è","{""skip"": true}"
2025-12-08T16:23:01+00:00,@medpharm,13925,https://t.me/medpharm/13925,"ü¶æ –ß–∞—Å–æ–≤ –Ω–µ –Ω–∞–±–ª—é–¥–∞—é—Ç. –§–µ–¥–µ—Ä–∞–ª—å–Ω—ã–µ –º–µ–¥—Ü–µ–Ω—Ç—Ä—ã –≤ –†–æ—Å—Å–∏–∏ –º–æ–≥—É—Ç —Ä–∞–±–æ—Ç–∞—Ç—å –≤ —Ä–µ–∂–∏–º–µ 24/7. –î–ª—è —ç—Ç–æ–≥–æ –æ–Ω–∏ –æ–±–µ—Å–ø–µ—á–µ–Ω—ã –Ω–µ–æ–±—Ö–æ–¥–∏–º—ã–º–∏ –∫–∞–¥—Ä–∞–º–∏ –∏ –æ–±—ä–µ–º–∞–º–∏ –º–µ–¥–ø–æ–º–æ—â–∏, –∑–∞—è–≤–∏–ª –º–∏–Ω–∏—Å—Ç—Ä –∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è –†–§ –ú–∏—Ö–∞–∏–ª –ú—É—Ä–∞—à–∫–æ. ü¶æ –û—Ç —â–µ–¥—Ä–æ—Ç. –í –ì–æ—Å–¥—É–º–µ –†–§ –ø—Ä–µ–¥–ª–æ–∂–∏–ª–∏ –≤—ã–ø–ª–∞—á–∏–≤–∞—Ç—å 13-—é –∑–∞—Ä–ø–ª–∞—Ç—É –≤—Ä–∞—á–∞–º –∏ –ø–µ–¥–∞–≥–æ–≥–∞–º –¥–ª—è –ø–æ–¥–¥–µ—Ä–∂–∫–∏ –∫–∞–¥—Ä–æ–≤ –∏ –ø–æ–≤—ã—à–µ–Ω–∏—è –ø—Ä–µ—Å—Ç–∏–∂–∞ –ø—Ä–æ—Ñ–µ—Å—Å–∏–π. –û–±—Ä–∞—â–µ–Ω–∏–µ –Ω–∞–ø—Ä–∞–≤–ª–µ–Ω–æ –≥–ª–∞–≤–µ –ú–∏–Ω—Ç—Ä—É–¥–∞ –†–§ –ê–Ω—Ç–æ–Ω—É –ö–æ—Ç—è–∫–æ–≤—É. ‚ù§Ô∏è –ü–æ–¥ –¥—Ä—É–≥–æ–π –≤—ã–≤–µ—Å–∫–æ–π. –ë–æ–ª–µ–µ 60 —Ç–æ—á–µ–∫ –º–æ—Å–∫–æ–≤—Å–∫–æ–π —Å–µ—Ç–∏ ¬´–°—Ç–æ–ª–∏—á–Ω—ã–µ –∞–ø—Ç–µ–∫–∏¬ª –ø–µ—Ä–µ—à–ª–∏ –ø–æ–¥ —É–ø—Ä–∞–≤–ª–µ–Ω–∏–µ –∫–æ–º–ø–∞–Ω–∏–∏ ¬´–†–∏–≥–ª–∞¬ª. –°–¥–µ–ª–∫–∞ –ø–æ –∞—Ä–µ–Ω–¥–µ —É–≤–µ–ª–∏—á–∏–ª–∞ –¥–æ–ª—é —Å–µ—Ç–∏ –≤ –ú–æ—Å–∫–≤–µ –¥–æ 12,5%. ‚ù§Ô∏è –õ–æ–ø–Ω—É–ª–æ —Ç–µ—Ä–ø–µ–Ω–∏–µ. –ì—É–±–µ—Ä–Ω–∞—Ç–æ—Ä –ö—É—Ä—Å–∫–æ–π –æ–±–ª–∞—Å—Ç–∏ —Ä–∞—Å–ø–æ—Ä—è–¥–∏–ª—Å—è –æ—Ç—Å—Ç—Ä–∞–Ω–∏—Ç—å –æ—Ç –∏—Å–ø–æ–ª–Ω–µ–Ω–∏—è –æ–±—è–∑–∞–Ω–Ω–æ—Å—Ç–µ–π –≥–µ–Ω–µ—Ä–∞–ª—å–Ω–æ–≥–æ –¥–∏—Ä–µ–∫—Ç–æ—Ä–∞ ¬´–ö—É—Ä—Å–∫–æ–π —Ñ–∞—Ä–º–∞—Ü–∏–∏¬ª. –ú–∞—Ç–µ—Ä–∏–∞–ª—ã –≤ –æ—Ç–Ω–æ—à–µ–Ω–∏–∏ —Ä—É–∫–æ–≤–æ–¥–∏—Ç–µ–ª—è —Ä–µ–≥–∏–æ–Ω–∞–ª—å–Ω–æ–π –∞–ø—Ç–µ—á–Ω–æ–π —Å–µ—Ç–∏ –±—É–¥—É—Ç –ø–µ—Ä–µ–¥–∞–Ω—ã –≤ –ø—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–∏—Ç–µ–ª—å–Ω—ã–µ –æ—Ä–≥–∞–Ω—ã.","{""skip"": true}"
2025-12-08T15:47:03+00:00,@medpharm,13924,https://t.me/medpharm/13924,"–ë–æ–ª–µ–µ 60 —Ç–æ—á–µ–∫ –º–æ—Å–∫–æ–≤—Å–∫–æ–π —Å–µ—Ç–∏ ¬´–°—Ç–æ–ª–∏—á–Ω—ã–µ –∞–ø—Ç–µ–∫–∏¬ª –ø–µ—Ä–µ—à–ª–∏ –ø–æ–¥ —É–ø—Ä–∞–≤–ª–µ–Ω–∏–µ –∫–æ–º–ø–∞–Ω–∏–∏ ¬´–†–∏–≥–ª–∞¬ª. –°–¥–µ–ª–∫–∞ –ø–æ –∞—Ä–µ–Ω–¥–µ —É–≤–µ–ª–∏—á–∏–ª–∞ –¥–æ–ª—é —Å–µ—Ç–∏ –≤ –ú–æ—Å–∫–≤–µ –¥–æ 12,5% –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjYyR #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–†–æ–∑–Ω–∏—Ü–∞","{""skip"": true}"
2025-12-08T15:30:01+00:00,@medpharm,13923,https://t.me/medpharm/13923,"–§–æ–∫—É—Å –Ω–∞ 2026 –¥–ª—è –∞–ø—Ç–µ–∫: –∞–ª—å—Ç–µ—Ä–Ω–∞—Ç–∏–≤–∞ –ø–æ–∫—É–ø–∫–µ —Å–æ—Ñ—Ç–∞, —Å–Ω–∏–∂–µ–Ω–∏–µ –∑–∞—Ç—Ä–∞—Ç –Ω–∞ –æ–±–æ—Ä—É–¥–æ–≤–∞–Ω–∏–µ –∏ –ø–æ–¥–≥–æ—Ç–æ–≤–∫–∞ –∫ —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è–º –¢–° –ü–ò–û–¢ –∏ –ù–î–° 22% –î–ª—è –∞–ø—Ç–µ—á–Ω–æ–≥–æ —Å–µ–∫—Ç–æ—Ä–∞ —É—Ö–æ–¥—è—â–∏–π –≥–æ–¥ –ø—Ä–∏–Ω–µ—Å –∑–Ω–∞—á–∏—Ç–µ–ª—å–Ω—ã–µ –∏–∑–º–µ–Ω–µ–Ω–∏—è –≤ –Ω–æ—Ä–º–∞—Ç–∏–≤–Ω–æ-–ø—Ä–∞–≤–æ–≤–æ–º —Ä–µ–≥—É–ª–∏—Ä–æ–≤–∞–Ω–∏–∏, –∫–æ—Ç–æ—Ä—ã–µ —Ç—Ä–µ–±—É—é—Ç –Ω–æ–≤—ã—Ö –ø–æ–¥—Ö–æ–¥–æ–≤ –∫ –∞–≤—Ç–æ–º–∞—Ç–∏–∑–∞—Ü–∏–∏. –°—Ä–µ–¥–∏ –∫–ª—é—á–µ–≤—ã—Ö –∞—Å–ø–µ–∫—Ç–æ–≤ ‚Äî–ø–µ—Ä–µ—Ö–æ–¥ –Ω–∞ –Ω–æ–≤—ã–µ —Ç–µ—Ö–Ω–æ–ª–æ–≥–∏—á–µ—Å–∫–∏–µ —Å—Ç–∞–Ω–¥–∞—Ä—Ç—ã, —Å–æ–∫—Ä–∞—â–µ–Ω–∏–µ –∑–∞—Ç—Ä–∞—Ç –Ω–∞ –∏–Ω—Ñ—Ä–∞—Å—Ç—Ä—É–∫—Ç—É—Ä—É –∏ –æ–ø—Ç–∏–º–∏–∑–∞—Ü–∏—è –æ–ø–µ—Ä–∞—Ü–∏–æ–Ω–Ω—ã—Ö –ø—Ä–æ—Ü–µ—Å—Å–æ–≤. –í—Å—ë —ç—Ç–æ –ø–æ–º–æ–∂–µ—Ç –∞–¥–∞–ø—Ç–∏—Ä–æ–≤–∞—Ç—å—Å—è –∫ –Ω–æ–≤—ã–º —É—Å–ª–æ–≤–∏—è —Ä–∞–±–æ—Ç—ã, —Ç–∞–∫–∏–º –∫–∞–∫ –ø–æ—Å—Ç–æ—è–Ω–Ω–æ –æ–±–Ω–æ–≤–ª—è—é—â–∏–µ—Å—è –Ω–æ–≤–æ–≤–≤–µ–¥–µ–Ω–∏—è –ø–æ –º–∞—Ä–∫–∏—Ä–æ–≤–∫–µ, –¢–° –ü–ò–û–¢, –Ω–æ–≤–∞—è —Å—Ç–∞–≤–∫–∞ –ù–î–°. –ö–æ–º–ø–∞–Ω–∏—è ¬´–°–ø–∞—Ä–≥–æ –¢–µ—Ö–Ω–æ–ª–æ–≥–∏–∏¬ª, —Ä–∞–∑—Ä–∞–±–æ—Ç—á–∏–∫ –ø—Ä–æ–≥—Ä–∞–º–º–Ω—ã—Ö —Ä–µ—à–µ–Ω–∏–π –¥–ª—è –∞–ø—Ç–µ–∫, —Ä–∞—Å—Å–∫–∞–∂–µ—Ç –ø—Ä–æ –æ—Å–Ω–æ–≤–Ω—ã–µ —Ç–µ–Ω–¥–µ–Ω—Ü–∏–∏, –∫–æ—Ç–æ—Ä—ã–µ –ø–æ–º–æ–≥—É—Ç –∞–ø—Ç–µ–∫–∞–º —Å–æ—Ö—Ä–∞–Ω–∏—Ç—å –∫–æ–Ω–∫—É—Ä–µ–Ω—Ç–æ—Å–ø–æ—Å–æ–±–Ω–æ—Å—Ç—å –≤ —É—Å–ª–æ–≤–∏—è—Ö –ø–æ—Å—Ç–æ—è–Ω–Ω—ã—Ö –ø–µ—Ä–µ–º–µ–Ω. –ò –ø—Ä–∏–≥–ª–∞—à–∞–µ—Ç –Ω–∞ –≤–µ–±–∏–Ω–∞—Ä 9 –¥–µ–∫–∞–±—Ä—è 2025 –≥–æ–¥–∞ –≤ 10:00. –ü–æ–¥—Ä–æ–±–Ω–æ—Å—Ç–∏ –∏ —Å—Ç—Ä–∞—Ç–µ–≥–∏—á–µ—Å–∫–∏–µ —Ä–µ–∫–æ–º–µ–Ω–¥–∞—Ü–∏–∏ –¥–ª—è –∞–ø—Ç–µ–∫ –Ω–∞ 2026 –≥–æ–¥: –ø–æ —Å—Å—ã–ª–∫–µ –†–µ–∫–ª–∞–º–∞, –ê–û ""–°–ø–∞—Ä–≥–æ –¢–µ—Ö–Ω–æ–ª–æ–≥–∏–∏""","{
  ""skip"": false,
  ""country"": ""global"",
  ""topic"": ""clinical_trial, guideline, pharmacovigilance, safety"",
  ""impact"": ""high"",
  ""english"": ""The year 2026 is focused on pharmacies: alternative to software purchase, reduction of equipment costs and preparation for T–° –ü–òogle requirements. This is a significant change in the regulatory framework affecting the pharmacy sector, requiring new approaches to automation. Key aspects include transitioning to new technological standards and optimizing operational processes to adapt to the constantly evolving conditions, such as updates on product marking, T–° –ü–òogle requirements, and a new VAT rate. Company 'Spargo Technologies', which develops software solutions for pharmacies, will discuss the main trends that help pharmacies maintain competitiveness in a constantly changing environment. The company invites to webinar on December 9, 2025 at 10:00. For more details and strategic recommendations for pharmacies in 2026, please refer to the link.""
}"
2025-12-08T15:19:08+00:00,@medpharm,13922,https://t.me/medpharm/13922,"–ó–∞–º–≥–ª–∞–≤—ã –°–∞–º–∞—Ä—Å–∫–æ–≥–æ –æ–±–ª–∞—Å—Ç–Ω–æ–≥–æ –±—é—Ä–æ —Å—É–¥–µ–±–Ω–æ-–º–µ–¥–∏—Ü–∏–Ω—Å–∫–æ–π —ç–∫—Å–ø–µ—Ä—Ç–∏–∑—ã –∑–∞–¥–µ—Ä–∂–∞–Ω –ø–æ –ø–æ–¥–æ–∑—Ä–µ–Ω–∏—é –≤ –ø–æ–ª—É—á–µ–Ω–∏–∏ –≤–∑—è—Ç–∫–∏. –°–ª–µ–¥—Å—Ç–≤–∏–µ —Å–≤—è–∑—ã–≤–∞–µ—Ç –¥–µ–ª–æ —Å –ê–ª–µ–∫—Å–∞–Ω–¥—Ä–æ–º –ö–∏—Ä–∏–ª–ª–æ–≤—ã–º, —Ä–∞–Ω–µ–µ –∑–∞–¥–µ—Ä–∂–∞–Ω–Ω—ã–º –∑–∞ –∞–Ω–∞–ª–æ–≥–∏—á–Ω–æ–µ –ø—Ä–µ—Å—Ç—É–ø–ª–µ–Ω–∏–µ. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjXVX #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ó–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏–µ #–î—Ä—É–≥–æ–µ","{""skip"": true}"
2025-12-08T14:57:03+00:00,@medpharm,13921,https://t.me/medpharm/13921,"FDA –æ–¥–æ–±—Ä–∏–ª–æ –ø–µ—Ä–≤—É—é CAR-T-—Ç–µ—Ä–∞–ø–∏—é –æ—Ç –ª–∏–º—Ñ–æ–º—ã –º–∞–Ω—Ç–∏–π–Ω–æ–π –∑–æ–Ω—ã. –ò—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è –ø–æ–∫–∞–∑–∞–ª–∏, —á—Ç–æ –ø—Ä–µ–ø–∞—Ä–∞—Ç –ø–æ–ª–Ω–æ—Å—Ç—å—é —É–±—Ä–∞–ª –æ–ø—É—Ö–æ–ª—å —É 62% –ø–∞—Ü–∏–µ–Ω—Ç–æ–≤. –í—ã–∂–∏–≤–∞–µ–º–æ—Å—Ç—å —Å–ø—É—Å—Ç—è –¥–≤–∞ –≥–æ–¥–∞ ‚Äî 90%. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjWHi #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–ü—Ä–æ–∏–∑–≤–æ–¥—Å—Ç–≤–æ","{""skip"": true}"
2025-12-08T14:37:07+00:00,@medpharm,13920,https://t.me/medpharm/13920,–ö—É—Ä–∞—Ç–æ—Ä –∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è –ö–æ—Å—Ç—Ä–æ–º—Å–∫–æ–π –æ–±–ª–∞—Å—Ç–∏ –ø–æ–∫–∏–Ω—É–ª–∞ –ø–æ—Å—Ç –∑–∞–º–ø—Ä–µ–¥–∞ –ø—Ä–∞–≤–∏—Ç–µ–ª—å—Å—Ç–≤–∞. –ï–µ –ø–æ–ª–Ω–æ–º–æ—á–∏—è –≤—Ä–µ–º–µ–Ω–Ω–æ –ø–µ—Ä–µ–¥–∞–ª–∏ –¥—Ä—É–≥–æ–º—É –∑–∞–º–µ—Å—Ç–∏—Ç–µ–ª—é –≥–ª–∞–≤—ã —Ä–µ–≥–∏–æ–Ω–∞ ‚Äî –ø–æ —Å—Ç—Ä–æ–∏—Ç–µ–ª—å—Å—Ç–≤—É. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjVAk #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ó–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏–µ #–û—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏—è_–∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è,"{""skip"": true}"
2025-12-08T13:58:03+00:00,@medpharm,13919,https://t.me/medpharm/13919,–°–∞–º–ì–ú–£ –ø–æ–ª—É—á–∏–ª –ª–∏—Ü–µ–Ω–∑–∏—é –Ω–∞ –ø—Ä–æ–∏–∑–≤–æ–¥—Å—Ç–≤–æ –∫–ª–µ—Ç–æ—á–Ω—ã—Ö –ø—Ä–æ–¥—É–∫—Ç–æ–≤ –¥–ª—è CAR-T-—Ç–µ—Ä–∞–ø–∏–∏. –ù–∞—á–∞–ª–æ –ø—Ä–æ–∏–∑–≤–æ–¥—Å—Ç–≤–∞ –∏–Ω–Ω–æ–≤–∞—Ü–∏–æ–Ω–Ω—ã—Ö –∫–ª–µ—Ç–æ—á–Ω—ã—Ö –ø—Ä–æ–¥—É–∫—Ç–æ–≤ –∑–∞–ø–ª–∞–Ω–∏—Ä–æ–≤–∞–Ω–æ –Ω–∞ 2026 –≥–æ–¥. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjSTq #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–†–µ–≥—É–ª—è—Ç–æ—Ä–∏–∫–∞,"{
  ""skip"": false,
  ""country"": ""global"",
  ""topic"": ""clinical_trial, regulation"",
  ""impact"": ""medium"",
  ""english"": ""SamGMU has obtained a license to produce cellular products for CAR-T therapy. Production of innovative cellular products is planned to start in 2026. For more details: https://clck.ru/3QjSTq #PharmNews #Regulation""
}"
2025-12-08T13:42:06+00:00,@medpharm,13918,https://t.me/medpharm/13918,"–§–æ–Ω–¥ ¬´–í—Ä–∞—á–µ–±–Ω–æ–µ –±—Ä–∞—Ç—Å—Ç–≤–æ¬ª –ø–æ–º–æ–≥–∞–µ—Ç –æ–∫–∞–∑—ã–≤–∞—Ç—å –ø–æ–¥–¥–µ—Ä–∂–∫—É —Å–µ–º—å—è–º –≤—Ä–∞—á–µ–π, –∏–º–µ—é—â–∏—Ö —Ç—è–∂–µ–ª–æ–±–æ–ª—å–Ω—ã—Ö –¥–µ—Ç–µ–π. –û–±—â–∞—è —Å—É–º–º–∞ —Å—Ä–µ–¥—Å—Ç–≤, –Ω–∞–ø—Ä–∞–≤–ª–µ–Ω–Ω—ã—Ö –Ω–∞ —ç—Ç—É –∏–Ω–∏—Ü–∏–∞—Ç–∏–≤—É, —Å–æ—Å—Ç–∞–≤–ª—è–µ—Ç 10,9 –º–ª–Ω —Ä—É–±–ª–µ–π. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjRKy #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ó–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏–µ #–î—Ä—É–≥–æ–µ","{""skip"": true}"
2025-12-08T11:52:02+00:00,@medpharm,13917,https://t.me/medpharm/13917,"–¶–µ–Ω—Ç—Ä –ª–µ–∫–æ–±–µ—Å–ø–µ—á–µ–Ω–∏—è –æ–±—ä—è–≤–∏–ª –ø—è—Ç—å –∞—É–∫—Ü–∏–æ–Ω–æ–≤ –Ω–∞ –∑–∞–∫—É–ø–∫—É –ø—Ä–µ–ø–∞—Ä–∞—Ç–æ–≤ –¥–ª—è –ª–µ—á–µ–Ω–∏—è –í–ò–ß –∏ –∏–Ω—Ñ–µ–∫—Ü–∏–π. –ö—Ä—É–ø–Ω–µ–π—à–∏–π –ª–æ—Ç ‚Äî –¥–æ—Ä–∞–≤–∏—Ä–∏–Ω –ª–∞–º–∏–≤—É–¥–∏–Ω —Ç–µ–Ω–æ—Ñ–æ–≤–∏—Ä –Ω–∞ 3,5 –º–ª—Ä–¥ —Ä—É–±–ª–µ–π. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjHmS #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–î–∏—Å—Ç—Ä–∏–±—É—Ü–∏—è","{
  ""skip"": false,
  ""country"": ""global"",
  ""topic"": ""tenders, shortage"",
  ""impact"": ""high"",
  ""english"": ""The Central Drug Supplies Center announced five tenders for the procurement of drugs to treat HIV and infections. The largest lot is darunavir lamivudine tenofovir for 3.5 billion rubles. More details: https://clck.ru/3QjHmS #PharmNews #Distribution""
}"
2025-12-08T11:47:04+00:00,@medpharm,13916,https://t.me/medpharm/13916,"–í –ì–æ—Å–¥—É–º–µ –†–§ –ø—Ä–µ–¥–ª–æ–∂–∏–ª–∏ –≤—ã–ø–ª–∞—á–∏–≤–∞—Ç—å 13-—é –∑–∞—Ä–ø–ª–∞—Ç—É –≤—Ä–∞—á–∞–º –∏ –ø–µ–¥–∞–≥–æ–≥–∞–º –¥–ª—è –ø–æ–¥–¥–µ—Ä–∂–∫–∏ –∫–∞–¥—Ä–æ–≤ –∏ –ø–æ–≤—ã—à–µ–Ω–∏—è –ø—Ä–µ—Å—Ç–∏–∂–∞ –ø—Ä–æ—Ñ–µ—Å—Å–∏–π. –¢–∞–∫–∞—è –º–µ—Ä–∞ –ø–æ–º–æ–∂–µ—Ç —Å–æ—Ö—Ä–∞–Ω–∏—Ç—å —Å–ø–µ—Ü–∏–∞–ª–∏—Å—Ç–æ–≤ –≤ —Ä–µ–≥–∏–æ–Ω–∞—Ö –∏ –ø—Ä–∏–≤–ª–µ—á—å –º–æ–ª–æ–¥–µ–∂—å –≤ –º–µ–¥–∏—Ü–∏–Ω—É –∏ –æ–±—Ä–∞–∑–æ–≤–∞–Ω–∏–µ, —Å—á–∏—Ç–∞—é—Ç –∞–≤—Ç–æ—Ä—ã –∏–Ω–∏—Ü–∏–∞—Ç–∏–≤—ã. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjHTh #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ó–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏–µ #–û—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏—è_–∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è","{""skip"": true}"
2025-12-08T10:31:06+00:00,@medpharm,13915,https://t.me/medpharm/13915,–§–µ–¥–µ—Ä–∞–ª—å–Ω—ã–µ –º–µ–¥—Ü–µ–Ω—Ç—Ä—ã –≤ –†–æ—Å—Å–∏–∏ –º–æ–≥—É—Ç —Ä–∞–±–æ—Ç–∞—Ç—å –≤ —Ä–µ–∂–∏–º–µ 24/7. –î–ª—è —ç—Ç–æ–≥–æ –æ–Ω–∏ –æ–±–µ—Å–ø–µ—á–µ–Ω—ã –Ω–µ–æ–±—Ö–æ–¥–∏–º—ã–º–∏ –∫–∞–¥—Ä–∞–º–∏ –∏ –æ–±—ä–µ–º–∞–º–∏ –º–µ–¥–ø–æ–º–æ—â–∏. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjCLk #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ó–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏–µ #–û—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏—è_–∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è,"{""skip"": true}"
2025-12-08T10:17:06+00:00,@medpharm,13914,https://t.me/medpharm/13914,–ö–∞–∫ –ø—Ä–µ–≤—Ä–∞—Ç–∏—Ç—å –Ω–∞—É—á–Ω—ã–π –ø—Ä–æ—Ä—ã–≤ –≤ —Ä—ã–Ω–æ—á–Ω—ã–π —É—Å–ø–µ—Ö –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjBRT #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–ú–Ω–µ–Ω–∏—è,"{""skip"": true}"
2025-12-08T10:15:02+00:00,@medpharm,13913,https://t.me/medpharm/13913,–ì—É–±–µ—Ä–Ω–∞—Ç–æ—Ä –ö—É—Ä—Å–∫–æ–π –æ–±–ª–∞—Å—Ç–∏ –ê–ª–µ–∫—Å–∞–Ω–¥—Ä –•–∏–Ω—à—Ç–µ–π–Ω —Ä–∞—Å–ø–æ—Ä—è–¥–∏–ª—Å—è –æ—Ç—Å—Ç—Ä–∞–Ω–∏—Ç—å –æ—Ç –∏—Å–ø–æ–ª–Ω–µ–Ω–∏—è –æ–±—è–∑–∞–Ω–Ω–æ—Å—Ç–µ–π –≥–µ–Ω–µ—Ä–∞–ª—å–Ω–æ–≥–æ –¥–∏—Ä–µ–∫—Ç–æ—Ä–∞ ¬´–ö—É—Ä—Å–∫–æ–π —Ñ–∞—Ä–º–∞—Ü–∏–∏¬ª –ò–≥–æ—Ä—è –û—Å–∏–ø–æ–≤–∞. –ú–∞—Ç–µ—Ä–∏–∞–ª—ã –≤ –æ—Ç–Ω–æ—à–µ–Ω–∏–∏ —Ä—É–∫–æ–≤–æ–¥–∏—Ç–µ–ª—è —Ä–µ–≥–∏–æ–Ω–∞–ª—å–Ω–æ–π –∞–ø—Ç–µ—á–Ω–æ–π —Å–µ—Ç–∏ –±—É–¥—É—Ç –ø–µ—Ä–µ–¥–∞–Ω—ã –≤ –ø—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–∏—Ç–µ–ª—å–Ω—ã–µ –æ—Ä–≥–∞–Ω—ã. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QjBE9 #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–†–æ–∑–Ω–∏—Ü–∞,"{""skip"": true}"
2025-12-08T08:52:03+00:00,@medpharm,13912,https://t.me/medpharm/13912,–£—á–µ–Ω—ã–µ —Ä–∞–∑—Ä–∞–±–æ—Ç–∞–ª–∏ —Ä–∞–±–æ—á—É—é –≤–∞–∫—Ü–∏–Ω—É –æ—Ç –í–ò–ß. –†–µ–∑—É–ª—å—Ç–∞—Ç—ã –∏—Å—Å–ª–µ–¥–æ–≤–∞–Ω–∏–π –ø—Ä–µ–¥—Å—Ç–∞–≤–∏–ª –ö–∞–ª–∏—Ñ–æ—Ä–Ω–∏–π—Å–∫–∏–π —É–Ω–∏–≤–µ—Ä—Å–∏—Ç–µ—Ç –≤ –°–∞–Ω-–§—Ä–∞–Ω—Ü–∏—Å–∫–æ. –ù–æ–≤—ã–π –º–µ—Ç–æ–¥ –ª–µ—á–µ–Ω–∏—è –í–ò–ß –ø–æ–∑–≤–æ–ª–∏–ª 70% –∏—Å–ø—ã—Ç—É–µ–º—ã—Ö –æ—Ç–∫–∞–∑–∞—Ç—å—Å—è –æ—Ç –∞–Ω—Ç–∏—Ä–µ—Ç—Ä–æ–≤–∏—Ä—É—Å–Ω–æ–π —Ç–µ—Ä–∞–ø–∏–∏. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3Qj4uf #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–ü—Ä–æ–∏–∑–≤–æ–¥—Å—Ç–≤–æ,"{""skip"": true}"
2025-12-08T08:11:06+00:00,@medpharm,13911,https://t.me/medpharm/13911,"–†–µ–≥—É–ª—è—Ç–æ—Ä—ã –Ω–µ –¥–µ–ª–∞—é—Ç –∏—Å–∫–ª—é—á–µ–Ω–∏—è –¥–ª—è —Å–ª—É—á–∞–µ–≤ —É—Ç–∏–ª–∏–∑–∞—Ü–∏–∏ –Ω–µ–∏—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–Ω–æ–≥–æ –º–µ–¥–∏–∑–¥–µ–ª–∏—è, —É—Ç–∏–ª–∏–∑–∏—Ä—É–µ–º–æ–≥–æ –ø–æ –ø—Ä–∏—á–∏–Ω–µ –∏—Å—Ç–µ—á–µ–Ω–∏—è —Å—Ä–æ–∫–∞ –≥–æ–¥–Ω–æ—Å—Ç–∏, —Ö—Ä–∞–Ω–µ–Ω–∏—è –∏ (–∏–ª–∏) —Å—Ä–æ–∫–∞ —Å–ª—É–∂–±—ã. –ö–∞–∫ —Å–¥–µ–ª–∞—Ç—å —ç—Ç–æ –ø—Ä–∞–≤–∏–ª—å–Ω–æ, –º–æ–∂–Ω–æ —É–∑–Ω–∞—Ç—å –∏–∑ —Ç–µ—Ö–Ω–∏—á–µ—Å–∫–æ–π –∏ —ç–∫—Å–ø–ª—É–∞—Ç–∞—Ü–∏–æ–Ω–Ω–æ–π –¥–æ–∫—É–º–µ–Ω—Ç–∞—Ü–∏–∏ –ø—Ä–æ–∏–∑–≤–æ–¥–∏—Ç–µ–ª—è (–∏–∑–≥–æ—Ç–æ–≤–∏—Ç–µ–ª—è). –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QiztY #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ó–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏–µ #–û—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏—è_–∑–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏—è","{
  ""skip"": true
}"
2025-12-08T07:55:02+00:00,@medpharm,13910,https://t.me/medpharm/13910,"–ö—Ä–∞—Å–Ω–æ–¥–∞—Ä—Å–∫–∞—è –∞–ø—Ç–µ–∫–∞ –≤–ø–∞–ª–∞ –≤ –Ω–∏—Ä–≤–∞–Ω—É –Ω–∞ 60 —Å—É—Ç–æ–∫. –ê—Ä–±–∏—Ç—Ä–∞–∂–Ω—ã–π —Å—É–¥ –ø—Ä–∏–æ—Å—Ç–∞–Ω–æ–≤–∏–ª –¥–µ—è—Ç–µ–ª—å–Ω–æ—Å—Ç—å –æ—Ä–≥–∞–Ω–∏–∑–∞—Ü–∏–∏ –∑–∞ –≥—Ä—É–±–æ–µ –Ω–∞—Ä—É—à–µ–Ω–∏–µ –ª–∏—Ü–µ–Ω–∑–∏–æ–Ω–Ω—ã—Ö —Ç—Ä–µ–±–æ–≤–∞–Ω–∏–π, —Å—Ä–µ–¥–∏ –∫–æ—Ç–æ—Ä—ã—Ö –Ω–∞–ª–∏—á–∏–µ –≤ –∞–ø—Ç–µ–∫–µ –ª–µ–∫–∞—Ä—Å—Ç–≤ –≤ –∏—Å—Ç–µ–∫—à–∏–º –≤ 2024 –≥–æ–¥—É —Å—Ä–æ–∫–æ–º –≥–æ–¥–Ω–æ—Å—Ç–∏, –∞ —Ç–∞–∫–∂–µ –ø—Ä–µ–ø–∞—Ä–∞—Ç–∞ –±–µ–∑ —ç—Ç–∏–∫–µ—Ç–∫–∏ –Ω–∞ —Ä—É—Å—Å–∫–æ–º —è–∑—ã–∫–µ —Å–æ —Å–ª–æ–≤–æ–º Nirvana –≤ –Ω–∞–∑–≤–∞–Ω–∏–∏, –æ—Ç—Å—É—Ç—Å—Ç–≤–∏–µ –º–µ–¥–∏–∫–∞–º–µ–Ω—Ç–æ–≤ –∏–∑ –æ–±—è–∑–∞—Ç–µ–ª—å–Ω–æ–≥–æ –º–∏–Ω–∏–º–∞–ª—å–Ω–æ–≥–æ –∞—Å—Å–æ—Ä—Ç–∏–º–µ–Ω—Ç–∞, –Ω–µ–≤–Ω–µ—Å–µ–Ω–∏–µ —Å–≤–µ–¥–µ–Ω–∏–π –≤ —Å–∏—Å—Ç–µ–º—ã –ï–ì–ò–°–ó –∏ –ú–î–õ–ü. –ü–æ–ª–Ω—ã–π —Å–ø–∏—Å–æ–∫ –ø—Ä–µ—Ç–µ–Ω–∑–∏–π —Ä–µ–≥—É–ª—è—Ç–æ—Ä–∞. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QiyfK #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–†–æ–∑–Ω–∏—Ü–∞","{
  ""skip"": false,
  ""country"": ""Russia"",
  ""topic"": ""sanctions, shortage"",
  ""impact"": ""high"",
  ""english"": ""A Redkino pharmacy in Krasnodar has been suspended for six days due to violations of licensing requirements, including expired medicines and a drug without Russian labeling. The regulator's full list of claims is available here: https://clck.ru/3QiyfK #PharmNews #Retail""
}"
2025-12-08T07:04:03+00:00,@medpharm,13909,https://t.me/medpharm/13909,"–≠–∫—Å–ø–µ—Ä—Ç—ã —Ñ–∞—Ä–º—Ä—ã–Ω–∫–∞ –æ–ø—Ä–µ–¥–µ–ª—è—é—Ç –Ω–æ–º–∏–Ω–∞–Ω—Ç–æ–≤, –∫–æ—Ç–æ—Ä—ã–µ –ø–µ—Ä–µ–π–¥—É—Ç –Ω–∞ II —ç—Ç–∞–ø –∏ –ø–æ–±–æ—Ä—é—Ç—Å—è –∑–∞ –∑–≤–∞–Ω–∏–µ –ø–æ–±–µ–¥–∏—Ç–µ–ª–µ–π —Å–µ–∑–æ–Ω–∞ –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3Qiv5f #–§–∞—Ä–º–≤–µ—Å—Ç–Ω–∏–∫ #–ü—Ä–æ–∏–∑–≤–æ–¥—Å—Ç–≤–æ","{""skip"": true}"
2025-12-08T06:29:03+00:00,@medpharm,13908,https://t.me/medpharm/13908,"–ë–æ–ª—å—à–µ –ø–æ–ª–æ–≤–∏–Ω—ã –ø–æ–ø—ã—Ç–æ–∫ –º–∞—Å—à—Ç–∞–±–∏—Ä–æ–≤–∞–Ω–∏—è –º–µ–¥–∏—Ü–∏–Ω—Å–∫–æ–≥–æ –±–∏–∑–Ω–µ—Å–∞ –∑–∞–∫–∞–Ω—á–∏–≤–∞—é—Ç—Å—è –ª–∏–±–æ —Å—Ç–∞–≥–Ω–∞—Ü–∏–µ–π, –ª–∏–±–æ —É–±—ã—Ç–∫–∞–º–∏. –ö–∞–∫ –ø–æ–Ω—è—Ç—å, —á—Ç–æ –≤–∞—à–∞ –∫–ª–∏–Ω–∏–∫–∞ –≥–æ—Ç–æ–≤–∞ –∫ —Ç–∞–∫–æ–º—É —ç–∫—Å–ø–µ—Ä–∏–º–µ–Ω—Ç—É. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QisgA #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ö–µ–π—Å—ã #–î—Ä—É–≥–æ–µ","{""skip"": true}"
2025-12-08T06:27:06+00:00,@medpharm,13907,https://t.me/medpharm/13907,–í –ü—Ä–æ–≥—Ä–∞–º–º—É –≥–æ—Å–≥–∞—Ä–∞–Ω—Ç–∏–π –ø–æ–≥—Ä—É–∑—è—Ç –Ω–æ–≤—ã–µ –æ–±—Å–ª–µ–¥–æ–≤–∞–Ω–∏—è –¥–ª—è –±–µ—Ä–µ–º–µ–Ω–Ω—ã—Ö. –ü–æ –∫—Ä–æ–≤–∏ –±—É–¥—É—â–µ–π –º–∞—Ç–µ—Ä–∏ –±–µ–∑ –∏–Ω–≤–∞–∑–∏–≤–Ω—ã—Ö –ø—Ä–æ—Ü–µ–¥—É—Ä –º–æ–∂–Ω–æ –±—É–¥–µ—Ç –æ–ø—Ä–µ–¥–µ–ª–∏—Ç—å —Ö—Ä–æ–º–æ—Å–æ–º–Ω—ã–µ –ø–µ—Ä–µ—Å—Ç—Ä–æ–π–∫–∏ –∏–ª–∏ –∏—Ö –∞–Ω–æ–º–∞–ª–∏–∏ —É –ø–ª–æ–¥–∞. –ü–æ–¥—Ä–æ–±–Ω–µ–µ: https://clck.ru/3QisWd #–ú–µ–¥–≤–µ—Å—Ç–Ω–∏–∫ #–ó–¥—Ä–∞–≤–æ–æ—Ö—Ä–∞–Ω–µ–Ω–∏–µ #–ê–∫—É—à–µ—Ä—Å—Ç–≤–æ_–∏_–≥–∏–Ω–µ–∫–æ–ª–æ–≥–∏—è #–î–∏–∞–≥–Ω–æ—Å—Ç–∏–∫–∞,"{
  ""skip"": true
}"
